Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DeLLphi-309: Phase 2 study of tarlatamab dosing regimens in small cell lung cancer
CTR20250807Phase 2Active
- Sponsor
- Amgen
- Start
- Mar 2025
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of tarlatamab in small cell lung cancer (SCLC), sponsored by Amgen. Started Mar 2025; status: active.
02
Drugs
tarlatamab
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20250807.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20250807.